ABSTRACT
This case report discusses the long-term follow-up of a patient with bilateral iridoschisis and Alport syndrome.
Subject(s)
Iris Diseases , Nephritis, Hereditary , Humans , Nephritis, Hereditary/complications , Follow-Up Studies , Iris Diseases/diagnosis , Iris Diseases/etiologyABSTRACT
Vitamin K plays a crucial role in the regulation of vascular calcifications by allowing activation of matrix Gla protein. The dietary requirement for vitamin K is low because of an efficient recycling of vitamin K by vitamin K epoxide reductase (VKORC1). However, decreased VKORC1 activity may result in vascular calcification. More than 30 coding mutations of VKORC1 have been described. While these mutations have been suspected of causing anticoagulant resistance, their association with an increase in the risk of vascular calcification has never been considered. We thus investigated functional cardiovascular characteristics in a rat model mutated in VKORC1. This study revealed that limited intake in vitamin K in mutated rat induced massive calcified areas in the media of arteries of lung, aortic arch, kidneys and testis. Development of calcifications could be inhibited by vitamin K supplementation. In calcified areas, inactive Matrix Gla protein expression increased, while corresponding mRNA expression was not modified. Mutation in VKORC1 associated with a limited vitamin K intake is thus a major risk for cardiovascular disease. Our model is the first non-invasive rat model that shows spontaneous medial calcifications and would be useful for studying physiological function of vitamin K.
Subject(s)
Arteriosclerosis/genetics , Monckeberg Medial Calcific Sclerosis/genetics , Vascular Calcification/genetics , Vitamin K Epoxide Reductases/genetics , Vitamin K/metabolism , Animals , Anticoagulants/administration & dosage , Aorta, Thoracic/pathology , Arteries/pathology , Arteriosclerosis/pathology , Disease Models, Animal , Humans , Kidney/blood supply , Kidney/pathology , Lung/blood supply , Lung/pathology , Male , Monckeberg Medial Calcific Sclerosis/pathology , Mutation , Mutation, Missense/genetics , Polymorphism, Single Nucleotide/genetics , Rats , Testis/blood supply , Testis/pathology , Vascular Calcification/pathology , Vitamin K/genetics , Vitamin K Epoxide Reductases/metabolismABSTRACT
Vitamin K is involved in the γ-carboxylation of the vitamin K-dependent proteins, and vitamin K epoxide is a by-product of this reaction. Due to the limited intake of vitamin K, its regeneration is necessary and involves vitamin K 2,3-epoxide reductase (VKOR) activity. This activity is known to be supported by VKORC1 protein, but recently a second gene, VKORC1L1, appears to be able to support this activity when the encoded protein is expressed in HEK293T cells. Nevertheless, this protein was described as being responsible for driving the vitamin K-mediated antioxidation pathways. In this paper we precisely analyzed the catalytic properties of VKORC1L1 when expressed in Pichia pastoris and more particularly its susceptibility to vitamin K antagonists. Vitamin K antagonists are also inhibitors of VKORC1L1, but this enzyme appears to be 50-fold more resistant to vitamin K antagonists than VKORC1. The expression of Vkorc1l1 mRNA was observed in all tissues assayed, i.e. in C57BL/6 wild type and VKORC1-deficient mouse liver, lung, and testis and rat liver, lung, brain, kidney, testis, and osteoblastic cells. The characterization of VKOR activity in extrahepatic tissues demonstrated that a part of the VKOR activity, more or less important according to the tissue, may be supported by VKORC1L1 enzyme especially in testis, lung, and osteoblasts. Therefore, the involvement of VKORC1L1 in VKOR activity partly explains the low susceptibility of some extrahepatic tissues to vitamin K antagonists and the lack of effects of vitamin K antagonists on the functionality of the vitamin K-dependent protein produced by extrahepatic tissues such as matrix Gla protein or osteocalcin.
Subject(s)
Anticoagulants/pharmacology , Liver/enzymology , Mixed Function Oxygenases/metabolism , Vitamin K Epoxide Reductases/metabolism , Animals , Biocatalysis/drug effects , Cell Line , Gene Expression Profiling , Gene Expression Regulation/drug effects , Humans , Kinetics , Liver/drug effects , Male , Mice , Mice, Inbred C57BL , Mixed Function Oxygenases/genetics , NAD(P)H Dehydrogenase (Quinone)/genetics , NAD(P)H Dehydrogenase (Quinone)/metabolism , Organ Specificity/drug effects , Organ Specificity/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Vitamin K/antagonists & inhibitors , Vitamin K/metabolism , Vitamin K Epoxide Reductases/deficiency , Vitamin K Epoxide Reductases/genetics , Warfarin/pharmacologyABSTRACT
The systematic use of antivitamin K anticoagulants (AVK) as rodenticides caused the selection of rats resistant to AVKs. The resistance is mainly associated to genetic polymorphisms in the Vkorc1 gene encoding the VKORC1 enzyme responsible for the reduction of vitamin K 2,3-epoxide to vitamin K. Five major mutations, which are responsible for AVK resistance, have been described. Possible explanations for the biological cost of these mutations have been suggested. This biological cost might be linked to an increase in the vitamin K requirements. To analyze the possible involvement of VKORC1 in this biological cost, rVKORC1 and its major mutants were expressed in Pichia pastoris as membrane-bound proteins and their catalytic properties were determined for vitamin K and 3-OH-vitamin K production. In this report, we showed that mutations at Leu-120 and Tyr-139 dramatically affect the vitamin K epoxide reductase activity. Moreover, this study allowed the detection of an additional production of 3-hydroxyvitamin K for all the mutants in position 139. This result suggests the involvement of Tyr-139 residue in the second half-step of the catalytic mechanism corresponding to the dehydration of vitamin K epoxide. As a consequence, the biological cost observed in Y139C and Y139S resistant rat strains is at least partially explained by the catalytic properties of the mutated VKORC1 involving a loss of vitamin K from the vitamin K cycle through the formation of 3-hydroxyvitamin K and a very low catalytic efficiency of the VKOR activity.